In ERβ+β/HER2- breast cancer, patients with PAM50 HER2-enriched tumors have an elevated relapse risk. The subtype is less estrogen dependent, while being highly proliferative, immune infiltrated and FGFR4-expressing, indicating novel therapy targets.
- Lennart Hohmann
- Kristin Sigurjonsdottir
- Johan Staaf
